BiondVax Pharmaceuticals Ltd.
BVXVNASDAQHealthcare
$1.36
+$0.01(+0.74%)
Market Cap$4966625
P/E Ratio—
52W High$11.49
52W Low$0.63
BiondVax Pharmaceuticals Ltd. (BVXV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BVXV · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.02B | $0.07B | $0.02B |
| G&A Expenses | $0.00B | $0.02B | $0.02B | $0.01B | $0.01B |
| Total Operating Expenses | $0.01B | $0.03B | ($0.00B) | $0.08B | $0.02B |
| Operating Income | ($0.01B) | ($0.03B) | $0.00B | ($0.08B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.00B | $0.01B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.04B) | ($0.00B) | ($0.11B) | ($0.02B) |
| Income Tax Expense | ($0.01B) | $0.01B | ($0.01B) | $0.01B | $0.00B |
| Net Income | ($0.00B) | ($0.05B) | $0.01B | ($0.12B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.20 | $-36.00 | $6.15 | $-151.98 | $-35.64 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.03B) | $0.01B | ($0.09B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · ILS · B
Explore more BiondVax Pharmaceuticals Ltd. data
About BiondVax Pharmaceuticals Ltd. (BVXV) Income Statement
BiondVax Pharmaceuticals Ltd. (BVXV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, BVXV reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
BVXV · 4 questionsBiondVax Pharmaceuticals Ltd. (BVXV) reported revenue of $0.00B for 2022, down —% year-over-year.
BVXV revenueBVXV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09